• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Disc Medicine Inc.

    11/14/24 5:44:55 PM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IRON alert in real time by email
    SC 13G/A 1 d911872dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, DC 20549

     

     

    SCHEDULE 13G

    (Rule 13d-102)

    Information to be Included in Statements Filed Pursuant

    to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed

    Pursuant to § 240.13d-2

    Under the Securities Exchange Act of 1934

    (Amendment No. 2)

     

     

    DISC MEDICINE, INC.

    (Name of Issuer)

     

     

    Common Stock, $0.0001

    par value per share

    (Title of Class of Securities)

    254604101

    (CUSIP Number)

    September 30, 2024

    (Date of Event Which Requires Filing of This Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (“Act”), or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 254604101   13G   Page 2 of 6 Pages

     

     1   

     Names of Reporting Persons

     

     Bain Capital Life Sciences Opportunities III, LP

     2  

     Check the Appropriate Box if a Member of a Group

     

     (a) ☐  (b) ☐

     3  

     SEC Use Only

     

     4  

     Citizenship or Place of Organization

     

     Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5   

     Sole Voting Power

     

     0 shares of Common Stock

       6  

     Shared Voting Power

     

     1,795,735 shares of Common Stock

       7  

     Sole Dispositive Power

     

     0 shares of Common Stock

       8  

     Shared Dispositive Power

     

     1,795,735 shares of Common Stock

     9   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     1,795,735 shares of Common Stock

    10  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

     ☐

    11  

     Percent of Class Represented by Amount in Row 9

     

     6.0%

    12  

     Type of Reporting Person

     

     PN


    CUSIP No. 254604101   13G   Page 3 of 6 Pages

     

    Item 1(a)

    Name of Issuer

    The name of the issuer to which this filing on Schedule 13G relates is Disc Medicine, Inc. (the “Issuer”).

     

    Item 1(b)

    Address of Issuer’s Principal Executive Offices

    The principal executive offices of the Issuer are located at 321 Arsenal Street, Suite 101, Watertown, Massachusetts 02472.

     

    Item 2(a)

    Name of Person Filing

    This Schedule 13G is being filed by Bain Capital Life Sciences Opportunities III, LP, a Delaware limited partnership (the “Reporting Person”).

    Bain Capital Life Sciences Investors, LLC, a Delaware limited liability company (“BCLSI”), is the manager of Bain Capital Life Sciences III General Partner, LLC, a Delaware limited liability company (“BCLS Fund III GP”), which is the general partner of Bain Capital Life Sciences Fund III, L.P., a Delaware limited partnership (“BCLS Fund III”), which is the sole member of Bain Capital Life Sciences Opportunities III GP, LLC, a Delaware limited liability company (together with the Reporting Person, BCLSI, BCLS Fund III GP and BCLS Fund III, the “Bain Capital Life Sciences Entities”), which is the general partner of the Reporting Person. As a result, BCLSI may be deemed to share voting and dispositive power with respect to the securities held by the Reporting Person.

     

    Item 2(b)

    Address of Principal Business Office or, if None, Residence

    The principal business address for each of the Bain Capital Life Sciences Entities is 200 Clarendon Street, Boston, Massachusetts 02116.

     

    Item 2(c)

    Citizenship

    Each of the Bain Capital Life Sciences Entities is organized under the laws of the State of Delaware.

     

    Item 2(d)

    Title of Class of Securities

    The class of securities of the Issuer to which this Schedule 13G relates is Common Stock, $0.0001 par value per share (“Common Stock”).

     

    Item 2(e)

    CUSIP Number

    The CUSIP number of the Common Stock is 254604101.

     

    Item 3

    If this statement is filed pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a

     

    (a)

      ☐    Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

    (b)

      ☐    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

    (c)

      ☐    Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

    (d)

      ☐    Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

    (e)

      ☐    An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

    (f)

      ☐    An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);


    CUSIP No. 254604101   13G   Page 4 of 6 Pages

     

    (g)

      ☐    A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

    (h)

      ☐    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

    (i)

      ☐    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);

    (j)

      ☐    A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);

    (k)

      ☐    Group, in accordance with § 240.13d-1(b)(1)(ii)(K).

    If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:

     

    Item 4

    Ownership

    (a) Amount beneficially owned:

    As of September 30, 2024, the Reporting Person held 1,795,735 shares of Common Stock, representing approximately 6.0% of the outstanding shares of Common Stock.

    The percentage of the outstanding shares of Common Stock held by the Reporting Person is based on 29,725,763 shares of Common Stock issued and outstanding as of August 5, 2024, as reported by the Issuer in its Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, filed with the Securities and Exchange Commission on August 8, 2024.

    (b) Percent of class:

    See Item 4(a) hereof.

    (c) Number of shares as to which the person has:

    (i) Sole power to vote or to direct the vote:

    0 shares of Common Stock

    (ii) Shared power to vote or to direct the vote:

    1,795,735 shares of Common Stock

    (iii) Sole power to dispose or to direct the disposition of:

    0 shares of Common Stock

    (iv) Shared power to dispose or to direct the disposition of:

    1,795,735 shares of Common Stock

     

    Item 5

    Ownership of Five Percent or Less of a Class

    Not applicable.

     

    Item 6

    Ownership of More Than Five Percent on Behalf of Another Person

    Not applicable.


    CUSIP No. 254604101   13G   Page 5 of 6 Pages

     

    Item 7

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person

    Not applicable.

     

    Item 8

    Identification and Classification of Members of the Group

    Not applicable.

     

    Item 9

    Notice of Dissolution of Group

    Not applicable.

     

    Item 10

    Certifications

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the Issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.


    CUSIP No. 254604101   13G   Page 6 of 6 Pages

     

    SIGNATURES

    After reasonable inquiry and to the best of its knowledge and belief, the undersigned certifies that the information in this statement is true, complete and correct.

     

    Dated: November 14, 2024     Bain Capital Life Sciences Opportunities III, LP
        By:   Bain Capital Life Sciences Opportunities III GP, LLC,
          its general partner
        By:   Bain Capital Life Sciences Fund III, L.P.,
          its sole member
        By:   Bain Capital Life Sciences III General Partner, LLC,
          its general partner
        By:   Bain Capital Life Sciences Investors, LLC,
          its manager
        By:  

    /s/ Ricky Sun

          Name: Ricky Sun
          Title:  Partner
    Get the next $IRON alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IRON

    DatePrice TargetRatingAnalyst
    7/21/2025$86.00Buy
    Truist
    7/3/2025$85.00Overweight
    Morgan Stanley
    6/11/2025$89.00Strong Buy
    Raymond James
    2/27/2025Buy
    TD Cowen
    11/5/2024$85.00Equal-Weight → Overweight
    Morgan Stanley
    11/4/2024$66.00 → $110.00Outperform → Strong Buy
    Raymond James
    10/23/2024$89.00Buy
    Jefferies
    10/16/2024Sector Outperform
    Scotiabank
    More analyst ratings

    $IRON
    SEC Filings

    View All

    SEC Form 144 filed by Disc Medicine Inc.

    144 - Disc Medicine, Inc. (0001816736) (Subject)

    8/22/25 4:29:56 PM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Disc Medicine Inc.

    144 - Disc Medicine, Inc. (0001816736) (Subject)

    8/22/25 4:25:35 PM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by Disc Medicine Inc.

    SCHEDULE 13D/A - Disc Medicine, Inc. (0001816736) (Subject)

    8/15/25 7:16:36 PM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IRON
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Bitterman Kevin sold $139,576 worth of shares (2,287 units at $61.03) (SEC Form 4)

    4 - Disc Medicine, Inc. (0001816736) (Issuer)

    8/26/25 6:01:57 PM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Bitterman Kevin sold $1,966,286 worth of shares (32,174 units at $61.11) (SEC Form 4)

    4 - Disc Medicine, Inc. (0001816736) (Issuer)

    8/15/25 7:23:46 PM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Bitterman Kevin sold $24,075 worth of shares (395 units at $60.95) (SEC Form 4)

    4 - Disc Medicine, Inc. (0001816736) (Issuer)

    8/7/25 5:00:08 PM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IRON
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Bitterman Kevin bought $8,000,028 worth of shares (222,223 units at $36.00) (SEC Form 4)

    4 - Disc Medicine, Inc. (0001816736) (Issuer)

    6/20/24 8:00:05 PM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Ashiya Mona bought $3,000,024 worth of shares (83,334 units at $36.00) (SEC Form 4)

    4 - Disc Medicine, Inc. (0001816736) (Issuer)

    6/20/24 5:27:54 PM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Orbimed Advisors Llc bought $3,000,024 worth of shares (83,334 units at $36.00) (SEC Form 4)

    4 - Disc Medicine, Inc. (0001816736) (Issuer)

    6/20/24 5:19:39 PM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IRON
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Disc Medicine to Participate in Upcoming Investor Conferences

    WATERTOWN, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that company management will participate in fireside chats at four upcoming investor conferences: Cantor Fitzgerald Global Healthcare Conference on Wednesday, September 3rd at 10:55 a.m. ET. 2025 Wells Fargo Healthcare Conference on Thursday, September 4th at 4:30 p.m. ET. H.C. Wainwright 27th Annual Global Investment Conference on Tuesday, September 9th at 12:00 p.m. ET.Morgan Stanley 23rd Annual Global He

    8/27/25 8:30:00 AM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Shattuck Labs Announces Closing of up to $103 Million Private Placement and Appointments to Board of Directors

    — Aggregate net proceeds from private placement expected to fund SL-325 through multiple Phase 2 clinical trials, including in Inflammatory Bowel Disease (IBD) and potentially another autoimmune disease — — Pro forma cash and cash equivalents, assuming full exercise of common stock warrants, expected to fund planned operations into 2029 — — Industry expert Dan Baker, M.D., and OrbiMed representative Mona Ashiya, Ph.D., appointed to the Board of Directors — AUSTIN, TX and DURHAM, NC, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily rece

    8/26/25 6:30:00 AM ET
    $IRON
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Disc Medicine Reports Second Quarter 2025 Financial Results and Provides Business Update

    Company on track to submit NDA for bitopertin in erythropoietic protoporphyria (EPP) under accelerated approval pathway in October 2025, supported by successful pre-NDA meetingExpect initial data from Phase 2 study of DISC-0974 in patients with anemia of myelofibrosis (MF) and multiple dose data from Phase 1b study of DISC-0974 in patients with anemia of non-dialysis-dependent chronic kidney disease (NDD-CKD) in Q4 2025Initiated Phase 2 study of DISC-3405 in polycythemia vera (PV) with initial data expected in 2026Presented positive clinical data updates across the portfolio at the European Hematology Association (EHA) Annual Congress, including longer term efficacy and safety data from the

    8/7/25 8:30:00 AM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IRON
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Truist initiated coverage on Disc Medicine with a new price target

    Truist initiated coverage of Disc Medicine with a rating of Buy and set a new price target of $86.00

    7/21/25 8:34:40 AM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Morgan Stanley resumed coverage on Disc Medicine with a new price target

    Morgan Stanley resumed coverage of Disc Medicine with a rating of Overweight and set a new price target of $85.00

    7/3/25 8:01:00 AM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Raymond James resumed coverage on Disc Medicine with a new price target

    Raymond James resumed coverage of Disc Medicine with a rating of Strong Buy and set a new price target of $89.00

    6/11/25 7:53:18 AM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IRON
    Leadership Updates

    Live Leadership Updates

    View All

    Disc Medicine Appoints Nadim Ahmed to its Board of Directors

    WATERTOWN, Mass., July 14, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the appointment of Nadim Ahmed to its Board of Directors. Mr. Ahmed is currently the President and Chief Executive Officer of Cullinan Therapeutics. "I am excited to welcome Nadim to Disc's Board of Directors at such a pivotal moment for the company," said John Quisel, J.D., Ph.D., President and Chief Executive Officer of Disc. "His track record of successful drug launches and deep expertise in hematological

    7/14/25 8:30:00 AM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Disc Medicine Reports Third Quarter 2024 Financial Results and Provides Business Update

    Completed a successful end of Phase 2 meeting with the FDA for bitopertin in erythropoietic protoporphyria (EPP), reaching alignment on all proposed study parameters with the potential for accelerated approval based on existing dataPresented proof-of-mechanism data for Phase 1b trial of DISC-0974 in patients with non-dialysis-dependent chronic kidney disease (NDD-CKD) and anemia at the American Society of Nephrology (ASN) Kidney Week 2024Eight posters and an oral presentation across all three clinical-stage assets to be presented at the 66th American Society of Hematology (ASH) Annual Meeting and ExpositionStrong financial position ending Q3 with $487 million in cash, cash equivalents, and m

    11/12/24 8:00:00 AM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Disc Medicine Appoints Seasoned Industry Executive Rahul Kaushik, Ph.D. as Chief Technical Officer

    WATERTOWN, Mass., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the appointment of Rahul Rajan Kaushik, Ph.D. as the company's Chief Technical Officer. Dr. Kaushik is an experienced biotech executive with significant expertise in chemistry, manufacturing, and controls (CMC) leadership across technical development, manufacturing and supply chain oversight for products in multiple modalities and therapeutic areas. "Rahul's experience is an ideal fit for Disc as we evolve in

    10/23/24 8:00:00 AM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IRON
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Disc Medicine Inc.

    SC 13G/A - Disc Medicine, Inc. (0001816736) (Subject)

    11/14/24 5:44:55 PM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Disc Medicine Inc.

    SC 13G/A - Disc Medicine, Inc. (0001816736) (Subject)

    11/14/24 4:33:10 PM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Disc Medicine Inc.

    SC 13G - Disc Medicine, Inc. (0001816736) (Subject)

    11/8/24 10:52:39 AM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IRON
    Financials

    Live finance-specific insights

    View All

    Disc Medicine Presents Positive Clinical Data Updates Across Portfolio at the European Hematology Association (EHA) 2025 Annual Congress

    Positive updates across all programs, including longer term efficacy and safety data from the HELIOS open-label extension trial of bitopertin in erythropoietic protoporphyria (EPP), additional durability data from Phase 1b study of DISC-0974 in anemia of myelofibrosis (MF), and additional data from DISC-3405 studies in healthy volunteersManagement to host a corporate update conference call on Monday, June 16 at 8:00 am ET / 2:00 pm CEST WATERTOWN, Mass., June 12, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematolo

    6/12/25 7:30:00 AM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2025 Congress

    Poster presentations across all programs, including data from HELIOS long-term extension trial of bitopertin in erythropoietic protoporphyria (EPP), additional durability data from Phase 1b study of DISC-0974 in anemia of myelofibrosis (MF), and additional data from DISC-3405 studies in healthy volunteersManagement will host a corporate update conference call on Monday June 16 at 8:00 am ET / 2:00 pm CEST WATERTOWN, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced that

    5/14/25 9:30:00 AM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Disc Medicine Announces Successful Type C Meeting with FDA for Bitopertin in Erythropoietic Protoporphyria (EPP) and Shares Plans for NDA Submission

    Pursuing accelerated approval for bitopertin in EPP with protoporphyrin IX (PPIX) reduction as the surrogate endpointPlanning to submit NDA under accelerated approval pathway in H2 2025 based on existing clinical data, including results from BEACON and AURORA Phase 2 trialsAchieved regulatory alignment on APOLLO post-marketing confirmatory trial design and on track to initiate trial by mid-year 2025Aligned on average monthly time in light without pain during the last month of the 6-month treatment period and percent change from baseline in whole-blood metal-free PPIX after 6 months of treatment as coprimary endpoints for confirmatory trialManagement will host a conference call on Tuesday, Ja

    1/21/25 7:45:00 AM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care